Breast Cancer

, Volume 5, Issue 4, pp 389–393 | Cite as

Efficacy and Significance of Sentinel Lymph Node Identification with Technetium-99m-labeled Tin Colloids for Breast Cancer

  • Kazuhiko Sato
  • Hoshio Hiraide
  • Minoru Uematsu
  • Kuniyoshi Tamaki
  • Hirofumi Ishikawa
  • Tamio Yamasaki
  • Seiichi Tamai
  • Shoichi Kusano
  • Hidetaka Mochizuki
Original Article



The sentinel lymph node (SLN) is thought to reflect the metastatic status of the remaining axillary lymph nodes in patients with breast cancer. We used technetium-99m-labeled tin colloids to identify SLN. The efficacy and significance of SLN identification using this method were investigated in terms of number, size, location, and tumor metastasis. The efficacy of the emulsion charcoal injection method for the intraoperative visible identification of SLN was also evaluated.


Twenty-five patients with invasive breast cancer were studied. Under ultrasonographic guidance, technetium-99m-labeled tin colloid particles (3 ml) were injected into 3 sites around the tumor within 3 mm of the margin or into the wall of the excisional biopsy cavity 2 hours before surgery. At surgery, just before the incision, an emulsion of charcoal particles (2.5 ml) was injected into 3 sites of the breast parenchyma surrounding the tumor. All patients underwent mastectomy with axillary dissection to the infraclavicular region. The radioactivity of each dissected lymph node was measured. All axillary specimens were processed in individual blocks for permanent section histopathologic evaluation with H &E.


SLN were defined as lymph nodes with 100 000 or more counts per minute (cpm) in radioactivity after injection of labeled tin colloids. In all 25 patients, SLN were identified (mean, 1.9 SLN/patient; range,l-4). Since the mean uptake in SLN was 383 124 cpm, but only 884 cpm in non-SLN nodes, discrimination between SLN and non-SLN nodes was easy. Clearly visible lymph nodes with charcoal staining accounted for 83.3% of all SLN, although 21.3% of non-SLN also stained. SLN were located only in the axillary region, but there were no other specific features in the location or size of SLN. The SLN were metastatic in 10 of the 25 patients: in 4, the SLN were the only metastatic nodes whereas in the remaining 6 patients, other axillary nodes were also positive. Fifteen patients with no metastasis in SLN had no tumor involvement in any other lymph nodes. There were no skip metastases.


SLN identified with labeled tin colloids have clinical value in predicting the metastatic status of the remaining axillary lymph nodes in breast cancer.

Key words

Breast cancer Axillary dissection Sentinel lymph node 



Sentinel lymph node(s)


Axillary lymph node dissection


Counts per minute

H & E

Hematoxylin and eosin staining


No significance


Sentinel lymph node dissection


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Wazer DE, Erban JK, Robert NJ,ea al: Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection.Cancer 74:878–883, 1994.PubMedCrossRefGoogle Scholar
  2. 2).
    Silverstein MJ, Giersen ED, Waisman JR,ea al: Axillary lymph node dissection for T1a carcinoma; Is it indicated?Cancer 73:664–667, 1994.PubMedCrossRefGoogle Scholar
  3. 3).
    Haffty BG, Ward B, Pathare P,ea al: Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer.J Clin Oncol 15:691–700, 1997.PubMedGoogle Scholar
  4. 4).
    Recht A, Houlihan MJ: Axillary lymph nodes and breast cancer; A review.Cancer 76:1491–1512, 1995.PubMedCrossRefGoogle Scholar
  5. 5).
    Copeland EM: Is axillary dissection necessary for T1 carcinoma of the breast?J Am Coll Surg 184:397–398, 1997.PubMedGoogle Scholar
  6. 6).
    Kissin MW, Querci della Rovere G, Easton D,ea al: Risk of lymphedema following the treatment of breast cancer.Br J Surg 73:580–585, 1986.PubMedCrossRefGoogle Scholar
  7. 7).
    Fisher B.Wolmark N, Bauer M,ea al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast.Surg Gynecol Obstet 152:765–772, 1981.PubMedGoogle Scholar
  8. 8).
    Moffat F, Senofsky G, Davis K,ea al: Axillary node dissection for early breast cancer; Some is good, but all is better.J Surg Oncol 51:8–13, 1992.PubMedCrossRefGoogle Scholar
  9. 9).
    Cabanas RM: An approach for the treatment of penile carcinoma.Cancer 39:456–466, 1977.PubMedCrossRefGoogle Scholar
  10. 10).
    Morton D, Wen D, Cochran A: Management of earlystage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy; An alternative to routine elective lymphadenectomy or “watch and wait”.Surg Oncol Clin N Am 1:247–259, 1992.Google Scholar
  11. 11).
    Morton D, Wen D, Wong J,ea al: Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 127:392–399, 1992.PubMedGoogle Scholar
  12. 12).
    Van der Veen H, Hoekstra OS, Paul MA,ea al: Gamma-probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy.Br J Surg 81:1769–1770, 1994.PubMedCrossRefGoogle Scholar
  13. 13).
    The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 12th ed, Kanehara, Tokyo, ppl-18, 1996.Google Scholar
  14. 14).
    Krag DN, Weaver DL, Alex C,ea al: Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe.Surg Oncol 2:335–340, 1993.PubMedCrossRefGoogle Scholar
  15. 15).
    Albertini JA, Lyman GH, Cox C,ea al: Lymphatic mapping and sentinel node biopsy in the patients with breast cancer.JAMA 276:1818–1822, 1996.PubMedCrossRefGoogle Scholar
  16. 16).
    Guiliano AE, Dale PS, Turner RB,ea al: Improved axillary staging of breast cancer with sentinel lymphadenectomy.Ann Surg; 222:394–401, 1995.CrossRefGoogle Scholar
  17. 17).
    Veronesi U, Paganelli G, Galimberti V,ea al: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.Lancet 349:1864–1867, 1997.PubMedCrossRefGoogle Scholar
  18. 18).
    Pijpers R, Meijer S, Hoekstra OS,ea al: Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer.J Nucl Med 38:366–368, 1997.PubMedGoogle Scholar
  19. 19).
    Alazraki N, Eshima D, Eshima L,ea al: Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers.Semin Nucl Med 27:55–67, 1997.PubMedCrossRefGoogle Scholar
  20. 20).
    Fujii K, Sawai K, Shimotsuma M,ea al: Study of lymphatic flow of mammary gland by application of activated carbon emulsion (CH44).J Jpn Soc Cancer Ther 21:96–102, 1986.Google Scholar
  21. 21).
    Veronesi U, Luini A, Galimberti V,ea al: Extent of metastatic axillary involvement in 1446 cases of breast cancer.Eur J Surg Oncol 16:127–133, 1990.PubMedGoogle Scholar
  22. 22).
    Turner RR, Ollila DW, Krasne DL,ea al: Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.Ann Surg 226:271–278, 1997.PubMedCrossRefGoogle Scholar
  23. 23).
    Noguchi M, Kawahara F, Tsugawa K,ea al: Sentinel lymphadenectomy in breast cancer; An alternative to routine axillary dissection.Breast Cancer 5:1–6, 1998.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1998

Authors and Affiliations

  • Kazuhiko Sato
    • 1
  • Hoshio Hiraide
    • 2
  • Minoru Uematsu
    • 3
  • Kuniyoshi Tamaki
    • 1
  • Hirofumi Ishikawa
    • 1
  • Tamio Yamasaki
    • 4
  • Seiichi Tamai
    • 5
  • Shoichi Kusano
    • 3
  • Hidetaka Mochizuki
    • 1
  1. 1.1st Department of SurgeryNational Defense Medical CollegeTokorozawaJapan
  2. 2.Research CenterNational Defense Medical CollegeJapan
  3. 3.Department of RadiologyNational Defense Medical CollegeJapan
  4. 4.lst Department of PathologyNational Defense Medical CollegeJapan
  5. 5.Department of Clinical PathologyNational Defense Medical CollegeJapan

Personalised recommendations